ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALXO Stock Price Chart Interactive Chart >
ALXO Price/Volume Stats
|Current price||$78.78||52-week high||$117.45|
|Prev. close||$77.37||52-week low||$32.51|
|Day high||$78.93||Avg. volume||245,526|
|50-day MA||$67.80||Dividend yield||N/A|
|200-day MA||$69.64||Market Cap||3.18B|
ALX Oncology Holdings Inc. (ALXO) Company Bio
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.
Most Popular Stories View All
ALXO Latest News Stream
|Loading, please wait...|
ALXO Latest Social Stream
View Full ALXO Social Stream
Latest ALXO News From Around the Web
Below are the latest news stories about Alx Oncology Holdings Inc that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma
-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer CenterBURLINGAME, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 1/2 investigator-sponsored trial of evorpacept (also known as ALX148), a next generation CD47 blocker, in combination with rituximab and lenalidomide for the
Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.
Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle.
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights. “We are pleased to report on the substantial progress we made since the prior quarter with our lead product candidate, ALX148, and that the United
ALXO Price Returns